Crown Bioscience Announces Expedited Access to Well-Established ATCC and NIH Cell Lines for Large-Scale Screening Panels
3.6.2021 15:30:00 EEST | Business Wire | Press release
Crown Bioscience (CrownBio), a JSR Life Sciences Company, today announced that they have entered into separate, yet complementary, portfolio license agreements with the ATCC and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute (NCI) of the National Institute of Health (NIH). By entering into five-year agreements with these premier biomaterial resource providers, CrownBio clients will directly benefit from a priority status that will make cell lines more readily available with simplified logistics.
Through its XenoSelect™ and OmniScreen™ panels, CrownBio already offers its clients highly customizable, broad in vitro screening panel services, paired with industry-leading bioinformatics capabilities and a breadth of established “matched” downstream in vivo models. CrownBio clients will now have access to an extended and unrivaled portfolio of cell lines, with the knowledge and peace of mind that all necessary licensing is in place.
The license agreement with ATCC grants CrownBio expedited access to more than 140 cell lines and associated datasets, as well as future access to an additional 4000 cell lines through an umbrella licensing structure. Similarly, to meet CrownBio’s ongoing global client needs for supplies of NIH cell lines, a new portfolio license has been signed with the NIH. With this agreement, CrownBio will provide access to 100 cell lines available through the NCI Repository of Tumors and Tumor Cell Lines and other sources, that were developed in NCI labs.
Henry Li, PhD, CSO of CrownBio said, “We greatly value our relationships with both ATCC and NIH, which are two of CrownBio’s largest cell line partners. We are excited that these new agreements will enable us to offer our clients expanded and prioritized cell line availability and supply. Together, these agreements exemplify CrownBio’s dedication to ensuring our clients have easy access to an industry-leading range of in vitro and in vivo models for drug discovery.”
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and immune-mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005538/en/
Contact information
Media Inquiries
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries
Gavin Cooper
Crown Bioscience Inc.
+1 518-488-9062
gavin.cooper@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 16:00:00 EET | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more customer interactions without a proportional increase in operational resources. Through collaboration with Google Cloud, Tigo is developing AI-assisted workflows to help opera
Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 16:00:00 EET | Press release
Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall short. A central finding of the survey is that speed is limited less by finding the signal, than by trusting it. Among pharma teams using AI, internal alignment (48%) and validation time (26%) are the le
REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202612.11.2026 15:41:00 EET | Press release
Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2026. The Group's consolidated turnover in the first nine months of the year reached €1,987.9 million, an increase of 9.2% compared to €1,819.8 million recorded on 30 September 2025. The indicators for the period are positive. Consolidated EBITDA was €354.9 million, equal to 17.9% of the consolidated revenues. As of September 2025 EBITDA was €335.5 million. EBIT, from January to September, reached €286.7 million, equal to 14.4% of the consolidated revenues. The corresponding 2025 figure was €281.0 million. Pre-tax profit, from January to September 2026, was €291.6 million, equal to 14.7% of the revenues. As of September 2025 pre-tax profit stood at €268.1 million. For the third quarter of the year, the Group’s performance is positive, with consolidated turnover for the period of €676.0 million compared to €598.5 million of the third quarter 2025. EBITDA, from July to September 2026, was equa
Klarna Names Chris Koegel as Chief Financial Officer12.11.2026 15:30:00 EET | Press release
Klarna Group plc (NYSE: KLAR), the everyday finance network, has appointed Chris Koegel as Chief Financial Officer, effective 1 January 2027, subject to regulatory approval. The appointment has been approved and endorsed by the Klarna Group plc board. He will succeed Niclas Neglén, who will remain CFO until the end of 2026. Koegel joins from Robinhood Markets Inc. (NASDAQ: HOOD), where he is Vice President, Head of Corporate Finance and Investor Relations. He joined Robinhood in 2022 and has served on the Leadership Team through a period of significant growth; the company’s valuation has grown from less than $10bn and has exceeded $100bn during his tenure. Before Robinhood, he was Head of Investor Relations at LPL Financial LLC (NASDAQ: LPLA) from 2015 to 2022, after spending 13 years at Bain & Company. Koegel has a BA in Mathematics from Williams College, an MBA from Dartmouth College, and is based in the US in the Boston, MA area. “Chris’s experience as a Finance leader at a US-liste
SLB Selected by Vår Energi for Integrated Drilling Services Offshore Norway12.11.2026 14:50:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111105994/en/ SLB (NYSE: SLB) has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. The selection covers an initial four-year period, with four additional one-year extension options that could extend the scope through 2034. Two harsh-environment semisubmersibles will continuously drill exploration and development wells during this period. The integrated delivery model brings together technical expertise, digital workflows and operational execution across the well delivery process. Working closely with Vår Energi and other selected
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom